Lipid-based nanoformulations in onychomycosis therapy: addressing challenges of current therapies and advancing treatment
RSC Advances · 2025 · 15 (10) · 7799-7825
DOI: 10.1039/d5ra00387c ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift RSC Advances, 2025. Verfasst von Shiv Kumar Prajapati und 2 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Pharmaceutical Research, GLA University Mathura India. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 222 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 3.0). Gefördert von: Birla Institute of Technology and Science, Pilani.
Abstract (Originalsprache)
Onychomycosis significantly impacts approximately 20% of the global population.
Autor:innen und Institutionen
- Institute of Pharmaceutical Research, GLA University Mathura India.
- Department of Pharmacy, Birla Institute of Technology and Science-Pilani Pilani Campus Pilani India ankit.j@pilani.bits-pilani.ac.in.
ORCID-Profile: Shiv Kumar Prajapati, Ankit Jain, Meenakshi Bajpai
Förderung
- Birla Institute of Technology and Science, Pilani
Zitieren
APA
Prajapati, S. K., Jain, A., & Bajpai, M. (2025). Lipid-based nanoformulations in onychomycosis therapy: addressing challenges of current therapies and advancing treatment. RSC Advances, 15(10), 7799-7825. https://doi.org/10.1039/d5ra00387c
Vancouver
Prajapati SK, Jain A, Bajpai M. Lipid-based nanoformulations in onychomycosis therapy: addressing challenges of current therapies and advancing treatment. RSC Advances. 2025;15(10):7799-7825. doi:10.1039/d5ra00387c
BibTeX
@article{Prajapati2025,
author = {Prajapati, Shiv Kumar and Jain, Ankit and Bajpai, Meenakshi},
title = {Lipid-based nanoformulations in onychomycosis therapy: addressing challenges of current therapies and advancing treatment},
journal = {RSC Advances},
year = {2025},
volume = {15},
number = {10},
pages = {7799--7825},
doi = {10.1039/d5ra00387c}
}
EUVIMED